NIBC brings Advicenne to Euronext Paris
Advicenne is a late-stage pharmaceutical company headquartered in Nimes, France, that focuses on the development of pediatric-friendly therapeutics to treat orphan renal and neurological diseases. Its most advanced product has shown positive results in a pivotal phase III study in children and adults. The product is also being developed for the treatment of Cystinuria, an inherited renal tubulopathy, for which it will begin clinical trials in 2018.
To help finance the commercialisation of its treatments, Advicenne opted to raise investor capital via a public listing of its shares. In August 2017 it turned to NIBC’s Life Sciences team for its in-depth sector and investor knowledge and to the Equity Capital Markets (ECM) team for its international reach among institutional investors.
NIBC acted as joint global coordinator, joint lead manager and joint bookrunner for the Initial Public Offering (IPO) on Euronext, Paris. Through the successful listing, Advicenne raised EUR 28.1 million to bring its lead drug to market in Europe and finalise further clinical trials in the United States.
NIBC’s Life Sciences and ECM teams demonstrated their skills and international reach among specialist and generalist institutional investors. The success of this Equity and Capital Markets transaction reflects NIBC´s approach of serving its clients with inventive tailor-made advisory and financing solutions.
The listing has enabled Advicenne to achieve its strategic objectives while greatly increasing its visibility. As a listed company it now has more options to grow its business as a pharmaceutical specialist.
Our IPO on Euronext Paris was a very fast process, we were very pleased with the work of all our partners including NIBC’s efficient support”. This fundraising is an important milestone for our company which was created 10 years ago - Luc-André Granier, CEO Advicenne